Medication info

Rosumax Tablet 20 Milligrams (Rosuvastatin Calcium)

Prescription medicationTabletExpired
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Jeongwoo Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets (15 tablets/PTP x 2 packs)
Approval status
Expired

MFDS item code 201903288 · Approved 2019.05.21

This product's status changed to Expired on 2024.05.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 ∼ 17 years): The usual dose range is 5 mg ∼ 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Jeongwoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medicine is used as an adjunct therapy in patients with primary hypercholesterolemia and mixed hyperlipidemia when diet and exercise do not adequately control these conditions. It is also helpful as an adjunct to lipid-lowering therapy in patients with homozygous familial hypercholesterolemia. It effectively lowers total cholesterol and LDL-cholesterol levels, limiting the progression of atherosclerosis. Furthermore, it is used as an adjunct to diet in pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia that meets specific criteria. It is beneficial for patients with primary dysbetalipoproteinemia; while there is no clinical evidence for the risk of coronary artery disease, it is used to reduce the risk of stroke, myocardial infarction, and arterial revascularization in middle-aged patients with cardiovascular disease risk factors. This medication effectively improves dyslipidemia and the risk of cardiovascular disease.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 ∼ 17 years): The usual dose range is 5 mg ∼ 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established in children under 10 years of age.

Precautions

This medication should not be used in patients with known allergies to specific ingredients. Patients with active liver disease or abnormally high liver enzyme levels should not take this medication. Patients with muscular disorders or myopathy should avoid this medication, and those taking cyclosporine should not use it concurrently. Patients with severe renal impairment and pregnant or breastfeeding women, as well as women of childbearing potential who are not using appropriate contraception, should not use this medication. The 40-milligram dosage is contraindicated for patients at high risk of muscle disorders, including those with moderate renal impairment, hypothyroidism, a history of hereditary muscular diseases, and alcohol abuse. This medication contains lactose and should not be administered to patients with lactose intolerance or related genetic disorders. Patients with high alcohol consumption or a history of liver disease should have regular liver function tests before and during treatment. If symptoms of myalgia or myopathy occur, immediate medical consultation and necessary testing should occur, and drug cessation may be required. If acute severe conditions or serious physical ailments are present, this medication should be discontinued. This medication may rarely trigger severe myasthenia gravis or ophthalmoplegic myasthenia; if such symptoms occur, discontinue use. The risk of muscular toxicity may increase when taken with certain other medications, so concomitant use must be checked. Renal function tests may be required for high-dose administration. Asian patients may have higher drug exposure, so dosages may need to be adjusted. This medication can also be used in children and adolescents, but growth and secondary sexual characteristics need to be monitored. Severe skin reactions may occur infrequently; if skin abnormality symptoms appear, medication use should be stopped immediately. This medication can interact with other drugs, so consult with healthcare providers if currently taking any other medications. Pregnant or breastfeeding women should not use this medication, and women of childbearing potential should practice appropriate contraception. In case of overdose, as there are no specific antidotes, treatment should be symptomatic along with liver function and muscle enzyme testing.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, drug-induced erythema multiforme, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to avoid exposure to air or moisture. It is best to keep the storage temperature between 1 to 30 degrees Celsius. This will help maintain the medication's efficacy for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets (15 tablets/PTP x 2 packs)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.